VRPX vs. AGRX, BPTSY, MBIO, SXTP, ONCO, BPTS, CWBR, NTBL, ARAV, and SNOA
Should you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Agile Therapeutics (AGRX), Biophytis (BPTSY), Mustang Bio (MBIO), 60 Degrees Pharmaceuticals (SXTP), Onconetix (ONCO), Biophytis (BPTS), CohBar (CWBR), Notable Labs (NTBL), Aravive (ARAV), and Sonoma Pharmaceuticals (SNOA). These companies are all part of the "pharmaceutical preparations" industry.
Virpax Pharmaceuticals (NASDAQ:VRPX) and Agile Therapeutics (NASDAQ:AGRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
Agile Therapeutics has higher revenue and earnings than Virpax Pharmaceuticals.
Virpax Pharmaceuticals has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, Agile Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.
In the previous week, Virpax Pharmaceuticals had 1 more articles in the media than Agile Therapeutics. MarketBeat recorded 9 mentions for Virpax Pharmaceuticals and 8 mentions for Agile Therapeutics. Agile Therapeutics' average media sentiment score of 0.38 beat Virpax Pharmaceuticals' score of 0.32 indicating that Agile Therapeutics is being referred to more favorably in the news media.
Virpax Pharmaceuticals has a net margin of 0.00% compared to Agile Therapeutics' net margin of -36.24%. Agile Therapeutics' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.
Agile Therapeutics received 422 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Virpax Pharmaceuticals an outperform vote while only 67.41% of users gave Agile Therapeutics an outperform vote.
Agile Therapeutics has a consensus target price of $8.50, indicating a potential upside of 2,150.46%. Given Agile Therapeutics' higher possible upside, analysts clearly believe Agile Therapeutics is more favorable than Virpax Pharmaceuticals.
32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.9% of Agile Therapeutics shares are owned by institutional investors. 6.2% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 0.5% of Agile Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Agile Therapeutics beats Virpax Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Virpax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virpax Pharmaceuticals Competitors List
Related Companies and Tools
